Khorramdelazad Hossein, Mortazavi Yousef, Momeni Mohammad, Arababadi Mohammad Kazemi, Khandany Behjat Kalantary, Moogooei Mozhgan, Hassanshahi Gholamhossein
Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran.
Department of Molecular Medicine, Faculty of Medicine, Zanjan University of Medical Sciences, 4513956111 Zanjan, Iran.
Indian J Hematol Blood Transfus. 2015 Mar;31(1):29-31. doi: 10.1007/s12288-014-0408-y. Epub 2014 Jun 19.
Chemokines and their receptors are crucially important in the pathogenesis of acute myeloblastic leukemia (AML). The CC chemokine receptor 5 (CCR5) is a specific chemokine receptor for CC chemokine ligand 3 (CCL3), CCL4 and CCL5 which all play key roles in identifying cancer properties and localization of leukemia cells. It has been demonstrated that the known mutation in CCR5 gene (CCR5-Δ32) leads to mal-expression of the receptor and affect its function. The aim of this study was to determine the rate of CCR5-Δ32 mutation within Iranian AML patients. In this study, blood samples were obtained from 60 AML patients and 300 healthy controls. The CCR5-Δ32 mutation was evaluated using Gap-PCR technique. Our results showed that CCR5-Δ32 mutation was not found in the patients, while three out of the controls had hetrozygotic form of this mutation. The rest of studied samples had the wild form of the gene. According to these findings, it can probably be concluded that the CCR5-Δ32 is not associated with susceptibility to AML in Iranian patients.
趋化因子及其受体在急性髓细胞白血病（AML）的发病机制中至关重要。CC趋化因子受体5（CCR5）是CC趋化因子配体3（CCL3）、CCL4和CCL5的特异性趋化因子受体，它们在识别癌症特性和白血病细胞定位中均发挥关键作用。已经证明，CCR5基因中的已知突变（CCR5-Δ32）会导致该受体表达异常并影响其功能。本研究的目的是确定伊朗AML患者中CCR5-Δ32突变的发生率。在本研究中，从60例AML患者和300例健康对照中采集血样。使用缺口聚合酶链反应（Gap-PCR）技术评估CCR5-Δ32突变。我们的结果显示，患者中未发现CCR5-Δ32突变，而对照组中有3人具有该突变的杂合形式。其余研究样本具有该基因的野生型。根据这些发现，可能可以得出结论，CCR5-Δ32与伊朗患者患AML的易感性无关。
